Heart attack prevention shot tested in 16,000 patients
NCT ID NCT03705234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 study tests a new cholesterol-lowering injection called inclisiran in over 16,000 people who have already had a heart attack, stroke, or artery surgery. The goal is to see if it safely reduces the risk of future heart attacks, strokes, or the need for emergency procedures. Participants receive either the injection or a placebo, and researchers track major heart events over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTSU, University of Oxford
Oxford, Oxfordshire, OX3 7LF, United Kingdom
-
TIMI Study Group
Boston, Massachusetts, 02115, United States